Navigation Links
In Clinical Trials, CAR T Cell Immunotherapy Continues to Yield Complete Responses in Children & Young Adults with Relapsed and Refractory Leukemia
Date:12/4/2016

SAN DIEGO, Dec. 3, 2016 /PRNewswire-USNewswire/ -- A highly innovative, personalized cell-based treatment for a high-risk form of the most common childhood cancer continues to move through clinical trials. Pediatric oncologists from Children's Hospital of Philadelphia today reported new results using T cell immunotherapy against relapsed or refractory acute lymphoblastic leukemia (ALL).

The physician-scientists presented findings at the annual meeting of the American Society of Hematology today in San Diego.

Continue Reading
Stephan A. Grupp, MD, PhD, director, Cancer Immunotherapy Frontier Program, Children's Hospital of Philadelphia
Stephan A. Grupp, MD, PhD, director, Cancer Immunotherapy Frontier Program, Children's Hospital of Philadelphia
Shannon L. Maude, MD, PhD, pediatric oncologist, Children's Hospital of Philadelphia
Shannon L. Maude, MD, PhD, pediatric oncologist, Children's Hospital of Philadelphia
Stephan A. Grupp, MD, PhD, director, Cancer Immunotherapy Frontier Program, Children's Hospital of Philadelphia Shannon L. Maude, MD, PhD, pediatric oncologist, Children's Hospital of Philadelphia

This immunotherapy modifies a patient's own immune T cells, extracted and engineered to potentially seek and destroy the patient's leukemia cells. The CHOP researchers reported on the first global, multicenter clinical trial of these cells and on a separate single-center trial, the first to use a version of these cells carrying a "humanized" protein more similar to human proteins.

In both trials, the patients were children and young adults who had relapsed after previous leukemia therapies, and/or had persistent (refractory) disease.

CHOP pediatric oncologist Stephan A. Grupp, MD, PhD, director of CHOP's Cancer Immunotherapy Frontier Program, co-moderated the ASH session on advances in immunotherapy for ALL at which these findings were presented. At this session, he reported results from the first global, multicenter trial of chimeric antigen receptor (CAR) T cells, of which he is the lead investigator.

This study, sponsored by Novartis, is a global registration trial—one that will provide data to submit to the U.S. Food and Drug Administration (FDA), requesting approval for clinical use. It has enrolled 81 patients at 25 centers in the U.S., Canada, Europe, Japan and Australia. Among the 50 patients who have received a single dose of the T cells, designated CTL019 cells, 41 patients (82 percent) had a complete response (that is, no detectable leukemia cells) within one to three months after treatment.

As in previous, single-center trials, the immunotherapy stimulated a sometimes severe side effect called cytokine release syndrome (CRS), which the researchers successfully managed, following an existing protocol. CRS can present as a flu-like illness with high fever and muscle aches, and can extend to requiring ICU-level care.

"Our results in this first international clinical trial are similar to what we saw in our single-center trials—in both the safety profile and high levels of effectiveness," said Grupp. Novartis aims to apply for FDA approval in 2017.

The research reflects an ongoing collaboration between Grupp, his colleagues in the Perelman School of Medicine at the University of Pennsylvania led by Carl H. June, MD, a co-author of the current study, and Novartis, the sponsor of the trial.

During the same ASH session, CHOP pediatric oncologist Shannon L. Maude, MD, PhD, presented findings from a pilot phase 1 study of "humanized" CAR T cells in 36 children and young adults with relapsed and refractory ALL. In this study, researchers modified CAR T cells to carry a CAR protein more similar to human protein than is the murine (mouse) protein used in CTL019 and other CD19-targeted CAR T cell treatments.

This trial, conducted at CHOP, is the first to use these humanized CAR T cells, called CTL119 cells. Of the 36 patients, 14 had previously been treated with murine CAR T cells. Some had shown no response, some relapsed after an initial response, and in some the CAR T cells did not persist well. Another 22 patients in the trial had not received previous CAR T cell treatment.

At one month after treatment, 30 patients showed a complete response, including 57 percent of those previously treated with murine CAR T cells, and 100 percent of the CAR-naive patients. At a median follow-up of seven months, 24 patients remained in remission. CRS occurred in 33 patients, but was mild in most patients, and was successfully managed in all.

"These CTL119 results are consistent with the high remission rates we have seen with CTL019," said Maude. "It is also encouraging that patients previously treated with CD19 CAR T cells could respond to humanized CTL119."

In 2012, Novartis acquired exclusive rights from Penn to CTL019. Several scientists from Novartis and Penn Medicine are co-authors of the abstracts presented by Grupp and Maude. Both Grupp and Maude are consultants to Novartis, and Grupp receives research funding from Novartis.

About Children's Hospital of Philadelphia: Children's Hospital of Philadelphia was founded in 1855 as the nation's first pediatric hospital. Through its long-standing commitment to providing exceptional patient care, training new generations of pediatric healthcare professionals, and pioneering major research initiatives, Children's Hospital has fostered many discoveries that have benefited children worldwide.  Its pediatric research program is among the largest in the country.  In addition, its unique family-centered care and public service programs have brought the 535-bed hospital recognition as a leading advocate for children and adolescents. For more information, visit http://www.chop.edu

Contact: Natalie Virgilio
Children's Hospital of Philadelphia
Office: (267) 426-6246
Virgilion@email.chop.edu

Photo - http://photos.prnewswire.com/prnh/20161202/445149
Photo - http://photos.prnewswire.com/prnh/20161202/445150

 

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/in-clinical-trials-car-t-cell-immunotherapy-continues-to-yield-complete-responses-in-children--young-adults-with-relapsed-and-refractory-leukemia-300372321.html


'/>"/>
SOURCE The Children's Hospital of Philadelphia
Copyright©2016 PR Newswire.
All rights reserved


Related medicine technology :

1. PipelineRx Presents Research and New Clinical Services Supporting Telepharmacy Offerings at ASHP Midyear Meeting
2. Europe Orphan Drug Market & Clinical Trial Insight 2015
3. Clinical Data for BackBeat Medicals Programmable Hypertension Control Therapy to Be Presented at ICI Meeting 2016
4. NIH Clinical Trial for Needle-free Zika Vaccine Showing Promise
5. Bracco Showcases Its Commitment to Diagnostic Imaging to Improve Patient Care and Clinical Outcomes at the 2016 Radiological Society of North America Annual Meeting (RSNA)
6. Research Presented at RSNA Shows Importance of Breast Imaging and Analytics Data to Improve Clinical Performance and Patient Satisfaction
7. DATATRAK Releases Powerful Clinical Trial Management System
8. Blueprint Medicines Announces Proof-of-Concept Data from Global Phase 1 Clinical Trial of BLU-554 in Patients with Advanced Hepatocellular Carcinoma
9. Worldwide Clinical Trials Webinar to Address Emerging Trends in Clinical Trial Methodology for Orphan Disease Drug Development
10. Ziehm Imaging sets new standards for clinical benefits at RSNA 2016
11. Neurotrope Completes Enrollment in its Randomized, Double-Blinded, Placebo-Controlled Phase 2 Clinical Trial of Bryostatin in Patients With Moderate to Severe Alzheimers Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/1/2017)... Ind. , Sept. 1, 2017  Explorers Like Us ... capture America,s greatest aural experiences — and deliver these experiences ... experience to help people feel and heal better. ... While nothing beats a ... and refresh your mind, Life Environments™ is the next best ...
(Date:8/31/2017)... Aug. 31, 2017 PM360,s annual Innovations ... to the latest innovations happening across the industry. Established ... to focus on providing a comprehensive look at the ... covers the most innovative companies, startups, divisions, products, services, ... "Everyone in this industry wants to ...
(Date:8/29/2017)... In a move that promises to exponentially ... veterinary practices of all sizes, Cubex LLC and The ... TITAN,s expertise in physical security, drug diversion investigations, staff ... "Every veterinary ... is at risk today," said TITAN founder and CEO, ...
Breaking Medicine Technology:
(Date:9/19/2017)... , ... September 19, 2017 , ... Public outrage over ... pollutants have fallen on deaf ears, leaving the water industry itself to research, develop ... stays ahead of the curve in the field of natural alkaline water ...
(Date:9/19/2017)... ... ... Bone Solutions Inc. (BSI), an orthobiologics technology company located ... OsteoCrete® bone void filler is designed to assist with bone repair and generation, ... for bone health and development. , “We’re excited to bring this important orthopedic ...
(Date:9/19/2017)... ... September 19, 2017 , ... Ron Norman, CEO of ... the importance of making a distinct rather than generic impression in the job market ... look through a stack of resumes knows that the first impression they give off ...
(Date:9/19/2017)... ... September 19, 2017 , ... Emergency ... the Certified Emergency Nurse (CEN®) certification according to a large-scale study ... of certification study, conducted by the Human Resources Research Organization (HumRRO) in late ...
(Date:9/18/2017)... ... 2017 , ... A September 7 article on BBC News describes ... the world’s most common and least expensive medications, may be able to stimulate stem ... of California Dental Group and Calabasas Dental Care says that, while it’s likely to ...
Breaking Medicine News(10 mins):